Surrozen (NASDAQ:SRZN) Releases Earnings Results, Misses Expectations By $2.04 EPS

Surrozen (NASDAQ:SRZN) issued its quarterly earnings data on Friday. The company reported ($3.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($2.04), Zacks reports. The firm had revenue of $0.98 million for the quarter.

Surrozen Stock Performance

SRZN opened at $8.35 on Friday. The stock has a market capitalization of $27.40 million, a price-to-earnings ratio of -0.33 and a beta of 0.69. The company has a fifty day moving average of $10.54 and a two-hundred day moving average of $10.95. Surrozen has a fifty-two week low of $6.00 and a fifty-two week high of $18.17.

Insider Activity at Surrozen

In related news, major shareholder Group Gp Lp Column III bought 1,034,482 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was acquired at an average cost of $11.60 per share, with a total value of $11,999,991.20. Following the purchase, the insider now directly owns 795,411 shares of the company’s stock, valued at $9,226,767.60. The trade was a -432.71 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 45.18% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Surrozen in a research report on Wednesday, April 2nd.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.